Erratum: Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system ((Proceedings of the National Academy of Sciences of the United States of America (2012) 109 (17597-17602) DOI: 10.1073/pnas.1209192109);Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 43, 2012, Pages 17597-17602

  Kirkby, Nicholas S ^a,b   Lundberg, Martina H ^a,b   Harrington, Louise S ^a   Leadbeater, Philip D M ^a   Milne, Ginger L ^c   Potter, Claire M F ^a   Al Yamani, Malak ^a,d   Adeyemi, Oladipupo ^a   Warner, Timothy D ^b   Mitchell, Jane A ^a,e  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c VANDERBILT UNIVERSITY   (United States)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e Institute of Cardiovascular Medicine (ICMS)   (United Kingdom)

Author keywords

Cox 2 selective drugs; Nonsteroidal anti inflammatory drugs; Rofecoxib; Thrombosis

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTACYCLIN;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR SYSTEM; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; METABOLITE; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SYSTEMIC CIRCULATION;

EID: 84867919301     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220901110     Document Type: Erratum

References (41)

1. Funk CD, FitzGerald GA (2007) COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 50:470-479. (Pubitemid 350146448)
2. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 116:4-15. (Pubitemid 43121782)
3. Warner TD, Mitchell JA (2008) COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371:270-273.
4. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866-12872.
5. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88:2692-2696. (Pubitemid 21916484)
6. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120. (Pubitemid 28231490)
7. Khan KN, Paulson SK, Verburg KM, Lefkowith JB, Maziasz TJ (2002) Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int 61:1210-1219. (Pubitemid 34304481)
8. Wallace JL, Devchand PR (2005) Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol 145:275-282. (Pubitemid 40896072)
9. Yu Z, et al. (2012) Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice. Proc Natl Acad Sci USA 109:6727-6732.
10. Yu Y, et al. (2012) Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med 4(132):132ra154.
11. McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med 8:e1001098.
12. Antman EM, et al.; American Heart Association (2007) Use of nonsteroidal antiinflammatory drugs: An update for clinicians: a scientific statement from the American Heart Association. Circulation 115:1634-1642. (Pubitemid 46648649)
13. McAdam BF, et al. (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272-277.
14. Catella-Lawson F, et al. (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289:735-741. (Pubitemid 29191226)
15. Mitchell JA, et al. (2006) Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J 20:2468-2475. (Pubitemid 44953819)
16. Zidar N, et al. (2009) Cyclooxygenase in normal human tissues - is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med 13(9B):3753-3763.
17. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ (2000) Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102:840-845.
18. Kawka DW, Ouellet M, Hétu PO, Singer II, Riendeau D (2007) Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochim Biophys Acta 1771:45-54. (Pubitemid 46073877)
19. Foudi N, Louedec L, Cachina T, Brink C, Norel X (2009) Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. Cardiovasc Res 81:269-277.
20. Mitchell JA, Warner TD (2006) COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 5:75-86.
21. Garcia-Cardeña G, Comander J, Anderson KR, Blackman BR, Gimbrone MA, Jr. (2001) Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 98:4478-4485. (Pubitemid 32295002)
22. Doroudi R, Gan LM, Selin Sjögren L, Jern S (2000) Effects of shear stress on eicosanoid gene expression and metabolite production in vascular endothelium as studied in a novel biomechanical perfusion model. Biochem Biophys Res Commun 269:257-264. (Pubitemid 30440287)
23. Topper JN, Cai J, Falb D, Gimbrone MA, Jr. (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93:10417-10422.
24. Di Francesco L, et al. (2009) Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. Circ Res 104:506-513.
25. Potter CM, et al. (2011) Role of shear stress in endothelial cell morphology and expression of cyclooxygenase isoforms. Arterioscler Thromb Vasc Biol 31:384-391.
26. Inoue H, et al. (2002) Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 22:1415-1420.
27. Okahara K, Sun B, Kambayashi J (1998) Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 18:1922-1926. (Pubitemid 28565755)
28. Iiyama K, et al. (1999) Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 85:199-207. (Pubitemid 29343319)
29. Hajra L, et al. (2000) The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA 97:9052-9057. (Pubitemid 30626672)
30. Suo J, et al. (2007) Hemodynamic shear stresses in mouse aortas: Implications for atherogenesis. Arterioscler Thromb Vasc Biol 27:346-351. (Pubitemid 46143050)
31. Liu B, et al. (2012) Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries. Exp Physiol 97:277-289.
32. Mitchell JA, et al. (1994) Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: Regulation by dexamethasone. Br J Pharmacol 113:1008-1014. (Pubitemid 24326847)
33. Cheng Y, et al. (2006) Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116:1391-1399.
34. Daniel VC, Minton TA, Brown NJ, Nadeau JH, Morrow JD (1994) Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 653:117-122. (Pubitemid 24085049)
35. Smith JP, et al. (2012) Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. Hypertension 59:719-725.
36. Carrier E, Brochu I, de Brum-Fernandes AJ, D'Orléans-Juste P (2007) The inducible nitric-oxide synthase modulates endothelin-1-dependent release of prostacyclin and inhibition of platelet aggregation ex vivo in the mouse. J Pharmacol Exp Ther 323:972-978. (Pubitemid 350146055)
37. Kaufmann WE, Andreasson KI, Isakson PC, Worley PF (1997) Cyclooxygenases and the central nervous system. Prostaglandins 54:601-624. (Pubitemid 27495921)
38. Langenbach R, et al. (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483-492.
39. Morham SG, et al. (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473-482.
40. Ballou LR, Botting RM, Goorha S, Zhang J, Vane JR (2000) Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci USA 97:10272-10276.
41. Armstrong PC, et al. (2011) Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. PLoS ONE 6:e20062.